Parkinson's disease biomarkers: resources for discovery and validation.
作者信息
Frasier Mark, Kang Un Jung
机构信息
The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.
出版信息
Neuropsychopharmacology. 2014 Jan;39(1):241-2. doi: 10.1038/npp.2013.246.
Abstract
摘要
相似文献
1
Parkinson's disease biomarkers: resources for discovery and validation.帕金森病生物标志物：发现与验证的资源
Neuropsychopharmacology. 2014 Jan;39(1):241-2. doi: 10.1038/npp.2013.246.
2
CSF and blood biomarkers for Parkinson's disease.脑脊液和血液生物标志物用于帕金森病的诊断。
Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10.
3
From metabolomics to proteomics: understanding the role of dopa decarboxylase in Parkinson's disease. Scientific commentary on: "Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease".从代谢组学到蛋白质组学：理解多巴脱羧酶在帕金森病中的作用。对《脑脊液、血浆和尿液的综合蛋白质组学鉴定出早期帕金森病的多巴脱羧酶及其他生物标志物》的科学评论
Acta Neuropathol. 2024 May 18;147(1):88. doi: 10.1007/s00401-024-02739-5.
4
Biomarkers for Parkinson's Disease: Recent Advancement.帕金森病的生物标志物：最新进展。
Neurosci Bull. 2017 Oct;33(5):585-597. doi: 10.1007/s12264-017-0183-5. Epub 2017 Sep 21.
5
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease.在帕金森病前驱期和新发帕金森病患者中，脑脊液中的多巴脱羧酶水平升高，但血浆中的多巴脱羧酶水平未升高。
Transl Neurodegener. 2024 Jun 11;13(1):31. doi: 10.1186/s40035-024-00421-0.
6
Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease.帕金森病患者脑脊液和血清中8-羟基鸟苷浓度的变化。
Neurosci Lett. 2003 Jan 16;336(2):105-8. doi: 10.1016/s0304-3940(02)01259-4.
7
Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.用于神经退行性疾病诊断和分类的基于血液的蛋白质生物标志物：当前进展和临床潜力。
Mol Diagn Ther. 2011 Apr 1;15(2):83-102. doi: 10.1007/BF03256398.
8
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.候选炎症生物标志物与α-突触核蛋白呈独特关系，并与帕金森病患者疾病严重程度的测量指标相关。
J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.
9
Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.帕金森病循环生物标志物的最新进展：微小RNA在临床环境中的潜在应用。
Bioanalysis. 2016 Dec;8(23):2497-2518. doi: 10.4155/bio-2016-0166.
10
Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.帕金森病中的 Tau/α-突触核蛋白比值与炎症蛋白：一项探索性研究。
Mov Disord. 2017 Jul;32(7):1066-1073. doi: 10.1002/mds.27001. Epub 2017 May 26.
引用本文的文献
1
Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.LRRK2 和 GBA 风险变异帕金森病患者的精准医学——让我们变得更加个体化。
Transl Neurodegener. 2020 Oct 16;9(1):39. doi: 10.1186/s40035-020-00218-x.
2
Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.帕金森病评定量表不同版本数据的项目反应模型适应性分析。
Pharm Res. 2019 Jul 17;36(9):135. doi: 10.1007/s11095-019-2668-6.
3
Unequivocal Biomarker for Parkinson's Disease: A Hunt that Remains a Pester.帕金森病的明确生物标志物：一项仍在困扰的探索。
Neurotox Res. 2019 Oct;36(3):627-644. doi: 10.1007/s12640-019-00080-4. Epub 2019 Jul 2.
4
Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients.项目反应理论作为一种有效的工具，可用于描述初发性特发性帕金森病患者中具有异质性的临床评分量表。
Pharm Res. 2017 Oct;34(10):2109-2118. doi: 10.1007/s11095-017-2216-1. Epub 2017 Jul 10.
本文引用的文献
1
Cerebrospinal fluid biomarkers in Parkinson disease.帕金森病的脑脊液生物标志物。
Nat Rev Neurol. 2013 Mar;9(3):131-40. doi: 10.1038/nrneurol.2013.10. Epub 2013 Feb 19.
2
The Parkinson Progression Marker Initiative (PPMI).帕金森进展标志物倡议（PPMI）。
Prog Neurobiol. 2011 Dec;95(4):629-35. doi: 10.1016/j.pneurobio.2011.09.005. Epub 2011 Sep 14.
3
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.血浆表皮生长因子水平可预测帕金森病患者认知能力下降。
Ann Neurol. 2011 Apr;69(4):655-63. doi: 10.1002/ana.22271. Epub 2010 Nov 29.
4
Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.人类脑脊液蛋白质组学：使用定量蛋白质组学发现和验证神经退行性疾病的生物标志物候选物。
J Proteomics. 2011 Apr 1;74(4):371-88. doi: 10.1016/j.jprot.2010.11.010. Epub 2010 Nov 25.
5
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.DJ-1 和α-突触核蛋白在人脑脊液中作为帕金森病的生物标志物。
Brain. 2010 Mar;133(Pt 3):713-26. doi: 10.1093/brain/awq008. Epub 2010 Feb 15.
6
Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients.针对氧化 DJ-1 的单克隆抗体的制备与应用。早发性帕金森病患者红细胞中氧化 DJ-1 水平显著升高。
Neurosci Lett. 2009 Nov 6;465(1):1-5. doi: 10.1016/j.neulet.2009.08.074. Epub 2009 Sep 3.
Zotero 插件